These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 2412251

  • 1. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.
    Garrick NA, Seppala T, Linnoila M, Murphy DL.
    Psychopharmacology (Berl); 1985; 86(3):265-9. PubMed ID: 2412251
    [Abstract] [Full Text] [Related]

  • 2. The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
    Garrick NA, Seppala T, Linnoila M, Murphy DL.
    Eur J Pharmacol; 1985 Mar 26; 110(1):1-9. PubMed ID: 2408906
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
    Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL.
    Biochem Pharmacol; 1984 May 01; 33(9):1423-7. PubMed ID: 6203542
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
    Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL.
    Psychopharmacology (Berl); 1987 May 01; 91(3):293-6. PubMed ID: 2436247
    [Abstract] [Full Text] [Related]

  • 5. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan 01; 240(1):251-8. PubMed ID: 3100771
    [Abstract] [Full Text] [Related]

  • 6. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
    Yoshino K.
    No To Shinkei; 1982 Nov 01; 34(11):1099-106. PubMed ID: 6186264
    [Abstract] [Full Text] [Related]

  • 7. Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.
    Strolin Benedetti M, Eschalier A, Lesage A, Dordain G, Rovei V, Zarifian E, Dostert P.
    Eur J Clin Pharmacol; 1984 Nov 01; 26(1):71-7. PubMed ID: 6538844
    [Abstract] [Full Text] [Related]

  • 8. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine.
    Asberg M, Ringberger VA, Sjöqvist F, Thorén P, Träskman L, Tuck JR.
    Clin Pharmacol Ther; 1977 Feb 01; 21(2):201-7. PubMed ID: 13959
    [Abstract] [Full Text] [Related]

  • 9. Repetitive measurement of monoamine metabolite levels in cerebrospinal fluid of conscious rats: effects of reserpine and haloperidol.
    Scheinin H, Scheinin M.
    Eur J Pharmacol; 1985 Jul 31; 113(3):345-51. PubMed ID: 2412847
    [Abstract] [Full Text] [Related]

  • 10. [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor].
    Poirier MF, Olié JP, Lôo H, Deniker P, Strolin Benedetti M, Rovei V, Lesage A.
    Encephale; 1983 Jul 31; 9(4):331-43. PubMed ID: 6368197
    [Abstract] [Full Text] [Related]

  • 11. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase.
    Dollery CT, Brown MJ, Davies DS, Lewis PJ, Strolin-Benedetti M.
    Clin Pharmacol Ther; 1983 Nov 31; 34(5):651-62. PubMed ID: 6627826
    [Abstract] [Full Text] [Related]

  • 12. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.
    Fowler CJ, Benedetti MS.
    J Neurochem; 1983 Jun 31; 40(6):1534-41. PubMed ID: 6406646
    [Abstract] [Full Text] [Related]

  • 13. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals--a genetic study.
    Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G.
    J Psychiatr Res; 1986 Jun 31; 20(1):19-29. PubMed ID: 2423688
    [Abstract] [Full Text] [Related]

  • 14. A longitudinal assessment of CSF monoamine metabolite and plasma cortisol concentrations in young rhesus monkeys.
    Higley JD, Suomi SJ, Linnoila M.
    Biol Psychiatry; 1992 Jul 15; 32(2):127-45. PubMed ID: 1384725
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and relative bioavailability studies of cimoxatone in humans.
    Rovei V, Mitchard M, Strolin Benedetti M, Kendall MJ.
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan 15; 22(1):56-62. PubMed ID: 6698662
    [Abstract] [Full Text] [Related]

  • 16. Plasma protein binding of the reversible type A MAO inhibitor cimoxatone (MD 780515).
    Rovei V, Chanoine F, Strolin Benedetti M, Zini R, Tillement JP.
    Biochem Pharmacol; 1983 Aug 01; 32(15):2303-8. PubMed ID: 6192825
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ.
    Br J Clin Pharmacol; 1990 Dec 01; 30(6):805-16. PubMed ID: 1705137
    [Abstract] [Full Text] [Related]

  • 18. Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta).
    Koutsilieri E, Götz ME, Sopper S, Stahl-Hennig C, Czub M, ter Meulen V, Riederer P.
    Neuroreport; 1997 Dec 01; 8(17):3833-6. PubMed ID: 9427379
    [Abstract] [Full Text] [Related]

  • 19. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
    Scheinin M.
    Med Biol; 1985 Dec 01; 63(1):1-17. PubMed ID: 2582215
    [Abstract] [Full Text] [Related]

  • 20. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
    Hjärpe J, Söderman E, Andreou D, Sedvall GC, Agartz I, Jönsson EG.
    Psychiatry Res; 2018 May 01; 263():30-34. PubMed ID: 29482043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.